### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Brian Thomas Campbell, et &

U.S. Serial No.: 10/527,044

Filed: March 8, 2005

For: FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS

Commissioner for Patents

et al.

OIPE

AN 2 4 7006 8

**Group No.:** 1626

Examiner: Freistein, Andrew

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION

[37 CFR 1.321]

I, David A. Rubin , residing at
126 East Lincoln Avenue, Rahway, New Jersey 07065-0907, am a representative
of the assignee identified below, empowered to act on its behalf, pursuant to attached Corporate Resolution No. 5, dated 04/23/2002
The assignee, Merck & Co., Inc.  that it is the assignee of the entire right, title and interest in the above-identified patent application by virtue of an Assignment from the inventor(s) in the aforesaid patent application, which was
recorded in the United States Patent & Trademark Office on Reel(s) 016752 Frame(s) 0286 on 09/08/2005,
was forwarded for recording on, with a copy of the recordation form and assignment attached hereto, or
is being concurrently forwarded for recording under separate cover, with a copy of the recordation form and assignment attached hereto.
The aforesaid assignment establishes the ownership in the assignee of the above-identified application pursuant to 37 CFR 3.73(b).
The undersigned has reviewed all of the evidentiary documents in the chain of title of the above-identified patent application, and the undersigned certifies that, to the best of the undersigned's knowledge and belief, title is in the assignee named above.
I hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of:
United States Patent No, or as presently shortened by any terminal disclaimer,
Any patent granted on application serial number $\frac{10/497,452}{10/497,452}$ ,

and hereby agree that any patent so gran enforceable on, for and during such per- same as the legal title to:	nted on the above-identified application shall be iods that the legal title to said patent shall be the
United States Patent No	······································
Any patent granted on application	serial number <u>10/497,452</u> ,
this agreement to run with any patent gr binding upon the grantor, its successors	ranted on the above-identified application and to be or assigns.
Petitioner does not disclaim any termina application prior to the expiration date of	al part of any patent granted on the above-identified of the full statutory term of:
United States Patent Noterminal disclaimer,	, or as presently shortened by any
Any patent granted on application	serial number <u>10/497,452</u> ,
is found invalid by a court of competent terminally disclaimed under 37 CFR 1.3 certificate, is reissued, or is otherwise to	tre to pay a maintenance fee, is held unenforceable, it jurisdiction, is statutorily disclaimed in whole or 321, has all claims canceled by a reexamination erminated prior to expiration of its full statutory hinal disclaimer, except for the separation of legal
•	ge Account No. 13-2755 the sum of \$130.00 paper. A duplicate of this disclaimer is attached.
statements made on information and be statements are made with the knowledg are punishable by fine or imprisonment	le herein of my own knowledge are true, and that all lief are believed to be true; and further, that these e that willful false statements and the like so made, or both, under Section 1001 of Title 18 of the ul false statements may jeopardize the validity of this n.
	Doug Ruli
	Disclaimant David A. Rubin
In Duplicate Attachs.  Date: 01/20/2006	Attorney Title Merck & Co., Inc. Patent Dept., RY60-30 P.O. Box 2000 Rahway, New Jersey 07065-0907 Telephone No. (732) 594-2675



# General Corporate Resolution #5

#### PATENT MATTERS

RESOLVED, that any of the following:

Richard T. Clark-Chief Executive Officer and President
Kenneth C. Frazier-Senior Vice President and General Counsel
Joseph F. DiPrima-Vice President and Assistant General Counsel
Paul D. Matukaitis-Vice President and Assistant General Counsel
William Krovatin-Counsel, IP Litigation
Edward W. Murray-Counsel, IP Litigation
Charles M. Caruso-Counsel, International
Valerie J. Camara-Counsel, Patents
Mark R. Daniel-Counsel, Patents
Joanne M. Giesser-Counsel, Patents
Anthony Rollins-Counsel, European Patents
David L. Rose-Counsel, Patents
Jack L. Tribble-Counsel, Patents
Melvin Winokur-Counsel, Patents
Donna L. Margiotto-Senior Manager, Patent Administration

are authorized to execute and to revoke on behalf of Merck & Co., Inc. and its affiliates (including subsidiaries) the following documents relating to patent matters:

Powers of attorney as fully in law as may be necessary and proper in connection with the acquisition, registration, maintenance and enforcement of patents and applications for patents, including powers of attorney relating to the prosecution or defense of patent rights before courts of law or other governmental tribunals, agencies or departments; affidavits and declarations; and any other documents which are necessary and proper for the acquisition, registration, maintenance, litigation and protection of patents.



## **CERTIFICATION**

I, Debra A. Bollwage, Senior Assistant Secretary of Merck & Co., Inc. (the "Company"), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the attached, presently in full force and effect, is a true and correct copy of General Corporate Resolution #5, Patent Matters, as amended by the Board of Directors of said Company at a meeting duly called and held on May 24, 2005.

IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 27<sup>th</sup> day of June 2005.

Senior Assistant Secretary

(SEAL)